Tower Research Capital LLC TRC bought a new position in Catalent Inc (NASDAQ:CTLT) during the second quarter, Holdings Channel reports. The fund bought 8,509 shares of the company’s stock, valued at approximately $196,000.
A number of other institutional investors have also modified their holdings of the company. Emerald Acquisition Ltd. acquired a new position in shares of Catalent during the second quarter worth about $123,000. LS Investment Advisors LLC boosted its position in shares of Catalent by 85.2% in the second quarter. LS Investment Advisors LLC now owns 7,131 shares of the company’s stock worth $164,000 after buying an additional 3,280 shares in the last quarter. Advisors Asset Management Inc. acquired a new position in shares of Catalent during the second quarter worth about $204,000. Strs Ohio boosted its position in shares of Catalent by 17.7% in the second quarter. Strs Ohio now owns 9,300 shares of the company’s stock worth $213,000 after buying an additional 1,400 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new position in shares of Catalent during the second quarter worth about $270,000.
Shares of Catalent Inc (NASDAQ:CTLT) opened at 25.60 on Friday. Catalent Inc has a 52 week low of $18.92 and a 52 week high of $32.24. The firm has a market cap of $3.19 billion and a price-to-earnings ratio of 28.76. The firm has a 50 day moving average of $25.21 and a 200 day moving average of $25.67.
Catalent (NASDAQ:CTLT) last posted its quarterly earnings data on Monday, August 29th. The company reported $0.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.53 by $0.01. The firm had revenue of $532.20 million for the quarter. During the same quarter in the prior year, the business posted $0.61 EPS. The business’s revenue was up 4.3% on a year-over-year basis. Equities analysts predict that Catalent Inc will post $1.40 earnings per share for the current fiscal year.
A number of equities analysts have issued reports on the stock. Jefferies Group reissued a “hold” rating and issued a $28.00 target price on shares of Catalent in a report on Thursday. Morgan Stanley reissued a “hold” rating on shares of Catalent in a report on Tuesday, August 30th. Wells Fargo & Co. raised shares of Catalent from a “market perform” rating to an “outperform” rating in a report on Tuesday, June 21st. Zacks Investment Research upgraded shares of Catalent from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 5th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $30.00 price target (down previously from $30.50) on shares of Catalent in a research note on Tuesday, August 30th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $28.67.
In other news, major shareholder Blackstone Management Associat sold 17,100,705 shares of the business’s stock in a transaction dated Friday, September 9th. The shares were sold at an average price of $23.58, for a total transaction of $403,234,623.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NASDAQ:CTLT).
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.